Analyst · Halozyme Therapeutics, Inc. (HALO) | Ratings, Price Targets & Consensus

Analyst Consensus

Buy13 analysts

Buy

Updated Aug 6, 2026

Total Analysts13

Buy

17

Hold

9

Sell

1

Ratings

Updated Aug 6, 2026

Overall Rating

B+

DCF Score4.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score2.0 / 5

ROA Score5.0 / 5

ROE Score5.0 / 5

Valuation

Current Stock Price

$85.76

Median Target-4.83%

$81.62

Potential downside vs current price

DCF Value+35.00%

$115.78

Potential upside vs current price

Current Stock Price

$85.76

Median Target-4.83%

$81.62

Potential downside vs current price

DCF Value+35.00%

$115.78

Potential upside vs current price

Analyst Consensus

Buy13 analysts

Buy

Updated Aug 6, 2026

Total Analysts13

Buy

17

Hold

9

Sell

1

Ratings

Updated Aug 6, 2026

Overall Rating

B+

DCF Score4.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score2.0 / 5

ROA Score5.0 / 5

ROE Score5.0 / 5

Valuation

Current Stock Price

$85.76

Median Target-4.83%

$81.62

Potential downside vs current price

DCF Value+35.00%

$115.78

Potential upside vs current price

Current Stock Price

$85.76

Median Target-4.83%

$81.62

Potential downside vs current price

DCF Value+35.00%

$115.78

Potential upside vs current price